{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:06:10Z","timestamp":1779296770936,"version":"3.51.4"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMP"],"published-print":{"date-parts":[[2020,7,9]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Small interfering RNAs (siRNAs) have rapidly developed into biomedical research as a\nnovel tool for the potential treatment of various human diseases. They are based on altered gene expression.\nIn spite of the availability of highly active antiretroviral therapy (HAART), there is a specific\ninterest in developing siRNAs as a therapeutic agent for human immunodeficiency virus (HIV) due to\nseveral problems including toxicity and drug resistance along with long term treatment. The successful\nuse of siRNAs for therapeutic goals needs safe and effective delivery to specific cells and tissues. Indeed,\nthe efficiency of gene silencing depends on the potency of the carrier used for siRNA delivery.\nThe combination of siRNA and nano-carriers is a potent method to prevent the limitations of siRNA\nformulation. Three steps were involved in non-viral siRNA carriers such as the complex formation of\nsiRNA with a cationic carrier, conjugation of siRNA with small molecules, and encapsulation of siRNA\nwithin nanoparticles.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>In this mini-review, the designed siRNAs and their carriers are described against HIV-1 infections both\nin vitro and in vivo.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1874467212666191023120954","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T09:37:10Z","timestamp":1574415430000},"page":"173-181","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Small Interfering RNAs and their Delivery Systems: A Novel Powerful Tool for the Potential Treatment of HIV Infections"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7363-7406","authenticated-orcid":true,"given":"Azam","family":"Bolhassani","sequence":"first","affiliation":[{"name":"Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Milani","sequence":"additional","affiliation":[{"name":"Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/125087","volume":"2014","author":"Wheeler L.A.","year":"2014","unstructured":"Wheeler L.A.; Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV. Infect Dis Obstet Gynecol 2014,2014","journal-title":"Infect Dis Obstet Gynecol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.imlet.2017.06.003","volume":"188","author":"Kadkhodayan S.","year":"2017","unstructured":"Kadkhodayan S.; Jafarzade B.S.; Sadat S.M.; Motevalli F.; Agi E.; Bolhassani A.; Combination of cell penetrating peptides and heterologous DNA prime\/protein boost strategy enhances immune responses against HIV-1 Nef antigen in BALB\/c mouse model. Immunol Lett 2017,188,38-45","journal-title":"Immunol Lett"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1515\/bmc-2015-0019","volume":"6","author":"Sarisozen C.","year":"2015","unstructured":"Sarisozen C.; Salzano G.; Torchilin V.P.; Recent advances in siRNA delivery. Biomol Concepts 2015,6(5-6),321-341","journal-title":"Biomol Concepts"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2005.03.010","volume":"22","author":"Bennasser Y.","year":"2005","unstructured":"Bennasser Y.; Le S.Y.; Benkirane M.; Jeang K.T.; Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity 2005,22(5),607-619","journal-title":"Immunity"},{"key":"ref=5","first-page":"74","volume":"7","author":"Tuzmen S.","year":"2018","unstructured":"Tuzmen S.; Yalinca Z.; Attractive approaches in siRNA delivery using polymer bio-based carrier systems. Anadolu Uni. J. Sci. Technol. C- Life Sci. Biotechnol 2018,7(1),74-89","journal-title":"Biotechnol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.drudis.2014.09.019","volume":"19","author":"Mishra V.","year":"2014","unstructured":"Mishra V.; Kesharwani P.; Jain N.K.; siRNA nanotherapeutics: a Trojan horse approach against HIV. Drug Discov Today 2014,19(12),1913-1920","journal-title":"Drug Discov Today"},{"key":"ref=7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025917","volume":"6","author":"Tyagi A.","year":"2011","unstructured":"Tyagi A.; Ahmed F.; Thakur N.; Sharma A.; Raghava G.P.S.; Kumar M.; HIVsirDB: a database of HIV inhibiting siRNAs. PLoS One 2011,6(10)","journal-title":"PLoS One"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4137\/EBO.S11412","volume":"9","author":"Vlachakis D.","year":"2013","unstructured":"Vlachakis D.; Tsiliki G.; Pavlopoulou A.; Roubelakis M.G.; Tsaniras S.C.; Kossida S.; Antiviral stratagems against HIV-1 using RNA interference (RNAi) technology. Evol Bioinform Online 2013,9,203-213","journal-title":"Evol Bioinform Online"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2144\/000112167","volume":"40","author":"Rossi J.J.","year":"2006","unstructured":"Rossi J.J.; RNAi as a treatment for HIV-1 infection. Biotechniques, 2006,40((Suppl.4-5)),25-29","journal-title":"Biotechniques,"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/mt.2009.271","volume":"18","author":"Kim S.S.","year":"2010","unstructured":"Kim S.S.; Peer D.; Kumar P.; Subramanya S.; Wu H.; Asthana D.; Habiro K.; Yang Y.G.; Manjunath N.; Shimaoka M.; Shankar P.; RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther 2010,18(2),370-376","journal-title":"Mol Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/978-1-61779-037-9_21","volume":"721,","author":"Kim S.S.","year":"2011","unstructured":"Kim S.S.; Subramanya S.; Peer D.; Shimaoka M.; Shankar P.; Antibody-mediated delivery of siRNAs for anti-HIV therapy. Methods in molecular biology Book series, 2011,721,,339-353","journal-title":"Methods in molecular biology Book series,"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1021\/acs.molpharmaceut.5b00335","volume":"12","author":"Adesina S.K.","year":"2015","unstructured":"Adesina S.K.; Akala E.O.; Nanotechnology approaches for the delivery of exogenous siRNA for HIV therapy. Mol Pharm 2015,12(12),4175-4187","journal-title":"Mol Pharm"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.imlet.2017.09.005","volume":"191","author":"Milani A.","year":"2017","unstructured":"Milani A.; Bolhassani A.; Shahbazi S.; Motevalli F.; Sadat S.M.; Soleymani S.; Small heat shock protein 27: An effective adjuvant for enhancement of HIV-1 Nef antigen-specific immunity. Immunol Lett 2017,191,16-22","journal-title":"Immunol Lett"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.imlet.2015.10.012","volume":"168","author":"Bolhassani A.","year":"2015","unstructured":"Bolhassani A.; Kardani K.; Vahabpour R.; Habibzadeh N.; Aghasadeghi M.R.; Sadat S.M.; Agi E.; Prime\/boost immunization with HIV-1 MPER-V3 fusion construct enhances humoral and cellular immune responses. Immunol Lett 2015,168(2),366-373","journal-title":"Immunol Lett"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/prot.25609","volume":"86","author":"Khairkhah N.","year":"2018","unstructured":"Khairkhah N.; Namvar A.; Kardani K.; Bolhassani A.; Prediction of cross-clade HIV-1 T-cell epitopes using immunoinformatics analysis. Proteins 2018,86(12),1284-1293","journal-title":"Proteins"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nm0702-659","volume":"8","author":"Pomerantz R.J.","year":"2002","unstructured":"Pomerantz R.J.; RNA interference meets HIV-1: will silence be golden? Nature Medicine, 2002,8,659-660","journal-title":"Nature Medicine,"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/35081168","volume":"411","author":"Novina, C.D.,","year":"2001","unstructured":"Novina, C.D.,; Murray, M.F.,; Dykxhoorn, D.M.,; Beresford P.J.; Riess J.; Lee S.K.; Collman R.G.; Waterhouse P.M.; Wang M.B.; Lough T.; Gene silencing as an adaptive defence against viruses. Nature 2001,411,834-842","journal-title":"Nature"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0960-9822(02)00975-2","volume":"12","author":"Hu W.Y.","year":"2002","unstructured":"Hu W.Y.; Myers C.P.; Kilzer J.M.; Pfaff S.L.; Bushman F.D.; Inhibition of retroviral pathogenesis by RNA interference. Curr Biol 2002,12(15),1301-1311","journal-title":"Curr Biol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.1093\/nar\/gkf627","volume":"30","author":"Park W.S.","year":"2002","unstructured":"Park W.S.; Miyano-Kurosaki N.; Hayafune M.; Nakajima E.; Matsuzaki T.; Shimada F.; Takaku H.; Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference. Nucleic Acids Res 2002,30(22),4830-4835","journal-title":"Nucleic Acids Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"Elbashir S.M.","year":"2001","unstructured":"Elbashir S.M.; Harborth J.; Lendeckel W.; Yalcin A.; Weber K.; Tuschl T.; Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001,411(6836),494-498","journal-title":"Nature"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"12963","DOI":"10.1128\/JVI.76.24.12963-12973.2002","volume":"76","author":"Surabhi R.M.","year":"2002","unstructured":"Surabhi R.M.; Gaynor R.B.; RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication. J Virol 2002,76(24),12963-12973","journal-title":"J Virol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nbt0502-500","volume":"20","author":"Lee N.S.","year":"2002","unstructured":"Lee N.S.; Dohjima T.; Bauer G.; Li H.; Li M.J.; Ehsani A.; Salvaterra P.; Rossi J.; Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002,20(5),500-505","journal-title":"Nat Biotechnol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nature00896","volume":"418","author":"Jacque J.M.","year":"2002","unstructured":"Jacque J.M.; Triques K.; Stevenson M.; Modulation of HIV-1 replication by RNA interference. Nature 2002,418(6896),435-438","journal-title":"Nature"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1128\/JVI.78.5.2601-2605.2004","volume":"78","author":"Das A.T.","year":"2004","unstructured":"Das A.T.; Brummelkamp T.R.; Westerhout E.M.; Vink M.; Madiredjo M.; Bernards R.; Berkhout B.; Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004,78(5),2601-2605","journal-title":"J Virol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nm725","volume":"8","author":"Novina C.D.","year":"2002","unstructured":"Novina C.D.; Murray M.F.; Dykxhoorn D.M.; Beresford P.J.; Riess J.; Lee S.K.; Collman R.G.; Lieberman J.; Shankar P.; Sharp P.A.; siRNA-directed inhibition of HIV-1 infection. Nat Med 2002,8(7),681-686","journal-title":"Nat Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/978-1-60327-547-7_17","volume":"487","author":"Mart\u00ednez M.A.","year":"2009","unstructured":"Mart\u00ednez M.A.; Progress in the therapeutic applications of siRNAs against HIV-1. Methods Mol Biol 2009,487,343-368","journal-title":"Methods Mol Biol"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1039\/b601381c","author":"Zhou J.","year":"2006","unstructured":"Zhou J.; Wu J.; Hafdi N.; Behr J.P.; Erbacher P.; Peng L.; PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun, 2006,2362-2364","journal-title":"Chem Commun,"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/iub.2107","volume":"71","author":"Rostami B.","year":"2019","unstructured":"Rostami B.; Irani S.; Bolhassani A.; Cohan R.A.; Gene and protein delivery using four cell penetrating peptides for HIV-1 vaccine development. IUBMB Life 2019,71(10),1619-1633","journal-title":"IUBMB Life"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1517\/14712598.2013.743526","volume":"13","author":"Lavigne C.","year":"2013","unstructured":"Lavigne C.; Slater K.; Gajanayaka N.; Duguay C.; Arnau Peyrotte E.; Fortier G.; Simard M.; Kell A.J.; Barnes M.L.; Thierry A.R.; Influence of lipoplex surface charge on siRNA delivery: application to the in vitro downregulation of CXCR4 HIV-1 co-receptor. Expert Opin Biol Ther 2013,13(7),973-985","journal-title":"Expert Opin Biol Ther"},{"key":"ref=30","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/719139","volume":"2011","author":"Mahajan S.D.","year":"2011","unstructured":"Mahajan S.D.; Aalinkeel R.; Reynolds J.L.; Nair B.; Sykes D.E.; Law W.C.; Ding H.; Bergey E.J.; Prasad P.N.; Schwartz S.A.; Nanotherapeutics using an HIV-1 poly A and transactivator of the HIV-1 LTR (TAR-) specific siRNA. Pathol Res Int 2011,2011","journal-title":"Pathol Res Int"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jconrel.2008.07.035","volume":"132","author":"Weber N.","year":"2008","unstructured":"Weber N.; Ortega P.; Clemente M.I.; Shcharbin D.; Bryszewska M.; de la Mata F.J.; G\u00f3mez R.; Mu\u00f1oz-Fern\u00e1ndez M.A.; Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. J Control Release 2008,132(1),55-64","journal-title":"J Control Release"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.bbamem.2013.11.017","volume":"1838","author":"Wrobel D.","year":"2014","unstructured":"Wrobel D.; Kolanowska K.; Gajek A.; Gomez-Ramirez R.; de la Mata J.; Pedziwiatr-Werbicka E.; Klajnert B.; Waczulikova I.; Bryszewska M.; Interaction of cationic carbosilane dendrimers and their complexes with siRNA with erythrocytes and red blood cell ghosts. Biochim Biophys Acta 2014,1838(3),882-889","journal-title":"Biochim Biophys Acta"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2165\/11538400-000000000-00000","volume":"24","author":"Jim\u00e9nez J.L.","year":"2010","unstructured":"Jim\u00e9nez J.L.; Clemente M.I.; Weber N.D.; Sanchez J.; Ortega P.; de la Mata F.J.; G\u00f3mez R.; Garc\u00eda D.; L\u00f3pez-Fern\u00e1ndez L.A.; Mu\u00f1oz-Fern\u00e1ndez M.A.; Carbosilane dendrimers to transfect human astrocytes with small interfering RNA targeting human immunodeficiency virus. BioDrugs 2010,24(5),331-343","journal-title":"BioDrugs"},{"key":"ref=34","doi-asserted-by":"publisher","DOI":"10.4081\/idr.2011.2370","volume":"3","author":"Eszterhas S.K.","year":"2011","unstructured":"Eszterhas S.K.; Ilonzo N.O.; Crozier J.E.; Celaj S.; Howell A.L.; Nanoparticles containing siRNA to silence CD4 and CCR5 reduce expression of these receptors and inhibit HIV-1 infection in human female reproductive tract tissue explants. Infect Dis Rep 2011,3(2)","journal-title":"Infect Dis Rep"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jconrel.2011.09.059","volume":"157","author":"Weber N.D.","year":"2012","unstructured":"Weber N.D.; Merkel O.M.; Kissel T.; Mu\u00f1oz-Fern\u00e1ndez M.\u00c1.; PEGylated poly(ethylene imine) copolymer-delivered siRNA inhibits HIV replication in vitro. J Control Release 2012,157(1),55-63","journal-title":"J Control Release"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1016\/j.biomaterials.2008.07.047","volume":"29","author":"Kim S.H.","year":"2008","unstructured":"Kim S.H.; Jeong J.H.; Ou M.; Yockman J.W.; Kim S.W.; Bull D.A.; Cardiomyocyte-targeted siRNA delivery by prostaglandin E(2)-Fas siRNA polyplexes formulated with reducible poly(amido amine) for preventing cardiomyocyte apoptosis. Biomaterials 2008,29(33),4439-4446","journal-title":"Biomaterials"},{"key":"ref=37","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/782041","volume":"2013","author":"Lee J.M.","year":"2013","unstructured":"Lee J.M.; Yoon T.J.; Cho Y.S.; Recent developments in nanoparticle-based siRNA delivery for cancer therapy. BioMed Res Int 2013,2013","journal-title":"BioMed Res Int"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/mt.2014.30","volume":"22","author":"Ding Y.","year":"2014","unstructured":"Ding Y.; Jiang Z.; Saha K.; Kim C.S.; Kim S.T.; Landis R.F.; Rotello V.M.; Gold nanoparticles for nucleic acid delivery. Mol Ther 2014,22(6),1075-1083","journal-title":"Mol Ther"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/anie.200604295","volume":"46","author":"Liu Z.","year":"2007","unstructured":"Liu Z.; Winters M.; Holodniy M.; Dai H.; siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew Chem Int Ed Engl 2007,46(12),2023-2027","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1093\/nar\/gkp185","volume":"37","author":"Zhou J.","year":"2009","unstructured":"Zhou J.; Swiderski P.; Li H.; Zhang J.; Neff C.P.; Akkina R.; Rossi J.J.; Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 2009,37(9),3094-3109","journal-title":"Nucleic Acids Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/mt.2008.92","volume":"16","author":"Zhou J.","year":"2008","unstructured":"Zhou J.; Li H.; Li S.; Zaia J.; Rossi J.J.; Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 2008,16(8),1481-1489","journal-title":"Mol Ther"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nm0310-258","volume":"16","author":"Dove A.","year":"2010","unstructured":"Dove A.; An apt approach. Nat Med 2010,16(3),258-260","journal-title":"Nat Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nbt940","volume":"22","author":"Kim D.H.","year":"2004","unstructured":"Kim D.H.; Longo M.; Han Y.; Lundberg P.; Cantin E.; Rossi J.J.; Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 2004,22(3),321-325","journal-title":"Nat Biotechnol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-1-4939-2432-5_11","volume":"848","author":"Takahashi M.","year":"2015","unstructured":"Takahashi M.; Burnett J.C.; Rossi J.J.; Aptamer-siRNA chimeras for HIV. Adv Exp Med Biol 2015,848,211-234","journal-title":"Adv Exp Med Biol"},{"key":"ref=45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135288","volume":"10","author":"Boyapalle S.","year":"2015","unstructured":"Boyapalle S.; Xu W.; Raulji P.; Mohapatra S.; Mohapatra S.S.; A multiple siRNA-based anti-HIV\/SHIV microbicide shows protection in both in vitro and in vivo models. PLoS One 2015,10(9)","journal-title":"PLoS One"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s13346-017-0368-5","volume":"7","author":"Gu J.","year":"2017","unstructured":"Gu J.; Al-Bayati K.; Ho E.A.; Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes. Drug Deliv Transl Res 2017,7(4),497-506","journal-title":"Drug Deliv Transl Res"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/mt.2012.226","volume":"21","author":"Zhou J.","year":"2013","unstructured":"Zhou J.; Neff C.P.; Swiderski P.; Li H.; Smith D.D.; Aboellail T.; Remling-Mulder L.; Akkina R.; Rossi J.J.; Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther 2013,21(1),192-200","journal-title":"Mol Ther"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.ymthe.2017.03.001","volume":"25","author":"Mizrahy S.","year":"2017","unstructured":"Mizrahy S.; Hazan-Halevy I.; Dammes N.; Landesman-Milo D.; Peer D.; Current progress in non-viral RNAi-based delivery strategies to lymphocytes. Molecular Therapy, 2017,25(7),1491-1500","journal-title":"Molecular Therapy,"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.7150\/thno.23085","volume":"8","author":"Zhou J.","year":"2018","unstructured":"Zhou J.; Lazar D.; Li H.; Xia X.; Satheesan S.; Charlins P.; O\u2019Mealy D.; Akkina R.; Saayman S.; Weinberg M.S.; Rossi J.J.; Morris K.V.; Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1. Theranostics 2018,8(6),1575-1590","journal-title":"Theranostics"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1038\/s41598-017-01819-9","volume":"7","author":"Rodriguez M.","year":"2017","unstructured":"Rodriguez M.; Lapierre J.; Ojha C.R.; Kaushik A.; Batrakova E.; Kashanchi F.; Dever S.M.; Nair M.; El-Hage N.; Intranasal drug delivery of small interfering RNA targeting Beclin1 encapsulated with polyethylenimine (PEI) in mouse brain to achieve HIV attenuation. Sci Rep 2017,7(1),1862","journal-title":"Sci Rep"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1038\/mt.2011.207","volume":"19","author":"Zhou J.","year":"2011","unstructured":"Zhou J.; Neff C.P.; Liu X.; Zhang J.; Li H.; Smith D.D.; Swiderski P.; Aboellail T.; Huang Y.; Du Q.; Liang Z.; Peng L.; Akkina R.; Rossi J.J.; Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther 2011,19(12),2228-2238","journal-title":"Mol Ther"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41434-019-0095-2","volume":"26","author":"Blakney A.K.","year":"2019","unstructured":"Blakney A.K.; McKay P.F.; Yus B.I.; Aldon Y.; Shattock R.J.; Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. Gene Ther 2019,26(9),363-372","journal-title":"Gene Ther"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nbt1101","volume":"23","author":"Song E.","year":"2005","unstructured":"Song E.; Zhu P.; Lee S.K.; Chowdhury D.; Kussman S.; Dykxhoorn D.M.; Feng Y.; Palliser D.; Weiner D.B.; Shankar P.; Marasco W.A.; Lieberman J.; Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005,23(6),709-717","journal-title":"Nat Biotechnol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s11481-012-9379-7","volume":"7","author":"Reynolds J.L.","year":"2012","unstructured":"Reynolds J.L.; Law W.C.; Mahajan S.D.; Aalinkeel R.; Nair B.; Sykes D.E.; Yong K.T.; Hui R.; Prasad P.N.; Schwartz S.A.; Nanoparticle based galectin-1 gene silencing, implications in methamphetamine regulation of HIV-1 infection in monocyte derived macrophages. J Neuroimmune Pharmacol 2012,7(3),673-685","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.omtn.2016.12.002","volume":"6","author":"Nozari A.","year":"2017","unstructured":"Nozari A.; Berezovski M.V.; Aptamers for CD antigens: From cell profiling to activity modulation. Mol Ther Nucleic Acids 2017,6,29-44","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"34","DOI":"10.32607\/20758251-2013-5-4-34-43","volume":"5","author":"Lakhin A.V.","year":"2013","unstructured":"Lakhin A.V.; Tarantul V.Z.; Gening L.V.; Aptamers: problems, solutions and prospects. Acta Naturae 2013,5(4),34-43","journal-title":"Acta Naturae"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"5196","DOI":"10.4049\/jimmunol.169.9.5196","volume":"169","author":"Capodici J.","year":"2002","unstructured":"Capodici J.; Karik\u00f3 K.; Weissman D.; Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J Immunol 2002,169(9),5196-5201","journal-title":"J Immunol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1021\/acs.molpharmaceut.5b00073","volume":"12","author":"Gu J.","year":"2015","unstructured":"Gu J.; Yang S.; Ho E.A.; Biodegradable film for the targeted delivery of siRNA-loaded nanoparticles to vaginal immune cells. Mol Pharm 2015,12(8),2889-2903","journal-title":"Mol Pharm"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"13542","DOI":"10.1021\/ja304649a","volume":"134","author":"Yan M.","year":"2012","unstructured":"Yan M.; Liang M.; Wen J.; Liu Y.; Lu Y.; Chen I.S.Y.; Single siRNA nanocapsules for enhanced RNAi delivery. J Am Chem Soc 2012,134(33),13542-13545","journal-title":"J Am Chem Soc"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"7912","DOI":"10.3390\/molecules18077912","volume":"18","author":"Peng J.","year":"2013","unstructured":"Peng J.; Wu Z.; Qi X.; Chen Y.; Li X.; Dendrimers as potential therapeutic tools in HIV inhibition. Molecules 2013,18,7912-7929","journal-title":"Molecules"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.colsurfb.2010.11.009","volume":"83","author":"Shcharbin D.","year":"2011","unstructured":"Shcharbin D.; Pedziwiatr E.; Nowacka O.; Kumar M.; Zaborski M.; Ortega P.; de la Mata F.J.; G\u00f3mez R.; Mu\u00f1oz-Fernandez M.A.; Bryszewska M.; Carbosilane dendrimers NN8 and NN16 form a stable complex with siGAG1. Colloids Surf B Biointerfaces 2011,83(2),388-391","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.bbamem.2012.04.019","volume":"1818","author":"Ionov M.","year":"2012","unstructured":"Ionov M.; Garaiova Z.; Waczulikova I.; Wr\u00f3bel D.; P\u0119dziwiatr-Werbicka E.; Gomez-Ramirez R.; de la Mata F.J.; Klajnert B.; Hianik T.; Bryszewska M.; siRNA carriers based on carbosilane dendrimers affect zeta potential and size of phospholipid vesicles. Biochim Biophys Acta 2012,1818(9),2209-2216","journal-title":"Biochim Biophys Acta"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"5044","DOI":"10.2174\/0929867311209025044","volume":"19","author":"Briz V.","year":"2012","unstructured":"Briz V.; Serram\u00eda M.J.; Madrid R.; Hameau A.; Caminade A.M.; Majoral J.P.; Mu\u00f1oz-Fern\u00e1ndez M.A.; Validation of a generation 4 phosphorus-containing polycationic dendrimer for gene delivery against HIV-1. Curr Med Chem 2012,19(29),5044-5051","journal-title":"Curr Med Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jconrel.2014.03.048","volume":"184","author":"Peris\u00e9-Barrios A.J.","year":"2014","unstructured":"Peris\u00e9-Barrios A.J.; Jim\u00e9nez J.L.; Dom\u00ednguez-Soto A.; de la Mata F.J.; Corb\u00ed A.L.; Gomez R.; Mu\u00f1oz-Fernandez M.\u00c1.; Carbosilane dendrimers as gene delivery agents for the treatment of HIV infection. J Control Release 2014,184,51-57","journal-title":"J Control Release"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejmech.2014.01.061","volume":"76","author":"S\u00e1nchez-Nieves J.","year":"2014","unstructured":"S\u00e1nchez-Nieves J.; Fransen P.; Pulido D.; Lorente R.; Mu\u00f1oz-Fern\u00e1ndez M.A.; Albericio F.; Royo M.; G\u00f3mez R.; de la Mata F.J.; Amphiphilic cationic carbosilane-PEG dendrimers: synthesis and applications in gene therapy. Eur J Med Chem 2014,76,43-52","journal-title":"Eur J Med Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jconrel.2014.12.042","volume":"200","author":"Serram\u00eda M.J.","year":"2015","unstructured":"Serram\u00eda M.J.; \u00c1lvarez S.; Fuentes-Paniagua E.; Clemente M.I.; S\u00e1nchez-Nieves J.; G\u00f3mez R.; de la Mata J.; Mu\u00f1oz-Fern\u00e1ndez M.A.; In vivo delivery of siRNA to the brain by carbosilane dendrimer. J Control Release 2015,200,60-70","journal-title":"J Control Release"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.cell.2008.06.034","volume":"134","author":"Kumar P.","year":"2008","unstructured":"Kumar P.; Ban H.S.; Kim S.S.; Wu H.; Pearson T.; Greiner D.L.; Laouar A.; Yao J.; Haridas V.; Habiro K.; Yang Y.G.; Jeong J.H.; Lee K.Y.; Kim Y.H.; Kim S.W.; Peipp M.; Fey G.H.; Manjunath N.; Shultz L.D.; Lee S.K.; Shankar P.; T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008,134(4),577-586","journal-title":"Cell"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ymeth.2010.12.039","volume":"54","author":"Zhou J.","year":"2011","unstructured":"Zhou J.; Shu Y.; Guo P.; Smith D.D.; Rossi J.J.; Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods 2011,54(2),284-294","journal-title":"Methods"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"66ra6","DOI":"10.1126\/scitranslmed.3001581","volume":"3","author":"Neff C.P.","year":"2011","unstructured":"Neff C.P.; Zhou J.; Remling L.; Kuruvilla J.; Zhang J.; Li H.; Smith D.D.; Swiderski P.; Rossi J.J.; Akkina R.; An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med 2011,3(66),66ra6","journal-title":"Sci Transl Med"}],"container-title":["Current Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/176072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T22:56:49Z","timestamp":1746572209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/176072\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874467212666191023120954","relation":{},"ISSN":["1874-4672"],"issn-type":[{"value":"1874-4672","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}